Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis.

ABSTRACT:

Background

The optimal first-line treatment for Rat Sarcorma Virus (RAS) wild-type metastatic colorectal cancer remains undetermined. Several studies have compared the efficacy of different first-line regimens, including doublet- or triplet-chemotherapy (CT) alone or in combination with targeted therapies (anti-EGFR/anti-VEGF), without conclusive results.

Methods

We conducted a systematic review and meta-analysis of phase II/III randomized clinical trials (RCT) comparing triplet-CT+anti-EGFRs with alternative first-line regimens in RAS wild-type patients. Pairwise- and network-meta-analyses were performed to assess overall response rate (ORR). Furthermore, we evaluated PFS and OS with pairwise-metanalyses.

Results

A total of 1283 patients across seven RCT were include

SUBMITTER: Di Nardo P 

PROVIDER: S-EPMC12923104 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature